View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 11, 2020

BD secures order for Covid-19 antigen tests from Canada

Medical technology company Becton, Dickinson and Company (BD) has received an order from the Canadian Government for 7.6 million point-of-care, rapid SARS-CoV-2 antigen tests and 2,172 analysers.

Medical technology company Becton, Dickinson and Company (BD) has received an order from the Canadian Government for 7.6 million point-of-care, rapid SARS-CoV-2 antigen tests and 2,172 analysers.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Last month, the test has been authorised by Health Canada for use on the BD Veritor Plus System under Interim Order.

The BD Veritor Plus System is already in use in the country for the diagnosis of influenza A+B, respiratory syncytial virus (RSV), and group A strep.

The Government of Canada will use the tests to scale up the testing efforts to contain the spread of the Covid-19 in the country.

Canada Public Services and Procurement minister Anita Anand said: “The Government of Canada continues to work diligently to provide Canadians with access to effective and efficient Covid-19 testing solutions.

“This new agreement with BD is critical to assisting the provinces and territories in their respective efforts to reduce the spread of the virus. We will continue to support Canadians through the Covid-19 pandemic.”

BD’s SARS-CoV-2 antigen test is designed to offer results in approximately 15 minutes and uses a mid-nasal swab to collect patient samples. It is considered to be less invasive for the patient than nasopharyngeal sample collection.

The test reduces the burden on testing laboratories as it is performed at the point-of-care.

BD Canada president Greg Miziolek said: “As the demands for SARS-CoV-2 testing are increasing in Canada, we are excited to bring another testing solution to the Canadian market.

“The ability to perform SARS-CoV-2 testing at the point-of-care and deliver results while the patient waits will be truly impactful to help relieve some of the pressures on the testing labs and quickly identify affected patients. We applaud the federal government for their proactive approach in planning for future needs with a centralised order for antigen detection tests.”

BD has also been supporting SARS-CoV-2 molecular testing (RT-PCR) in Canadian labs on the BD MAX System.

Earlier this month, BD secured an order from the Dutch Ministry of Health for 9.2 million of its SARS-CoV-2 antigen tests for use on the BD Veritor Plus System.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network